focus -WSS

focus

author：entertainment 2025-10-03 00:07:16 - browse：439

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： MassMutual is introducing free genetic testing for members

WSS

A bus careens into a gulch in southern Mexico, leaving 27 people dead

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

More tobacco lobbyists active in statehouses

Close Medicare's dangerous gaps in addiction treatment coverage

Exact Sciences stock tumbles despite strong cancer detection sales

Health care needs a new profession: neuroimaging counseling

Wikipedia

focus

leisure time

23andMe had bad news about my health. I wish a person had delivered it

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

Medical records are filled with copy

Cell therapy fails to slow type 1 diabetes, but safety is established

Sports medicine is finally prioritizing gender equality

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

United colonoscopy coverage change 'may cost lives,' doctors say

Why does health care cost so much? A reading guide

Activists slam private health insurers over coverage restrictions

Condition critical? Britain's beloved but battered National Health Service turns 75

knowledge

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Adele warns fans about throwing things at performers onstage

Israel withdraws forces after 2

Getting Alzheimer's drug Leqembi to patients can be a challenge

Cholera vaccine supply gets boost as demand surges globally

Medical bills so high, Medicare adding extra digits to claim forms

hotspot

leisure time

entertainment

leisure time